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Abstract 
Toll Like Receptors (TLRs) are pathogen recognition molecules with 
widespread expression in the cells and tissues. Among them, TLR4 is 
involved in several important diseases. TLR4 can be stimulated by 
endogenous ligands as well as bacteria and viruses. TLR4 stimulation on the 
surface of monocytes leads to production of pro-inflammatory cytokines. It is 
documented that mechanical ventilation with tidal volumes of 40 mL/kg is 
able to induce inflammation. The mechanism of action of mechanical 
ventilation may involve increasing in TLR2 and TLR4 expression. Here we 
review the current understanding about TLR4 and lung injuries in basic and 
clinical science.  
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Introduction 
Toll like receptors (TLRs) recognize pathogens 
and generate an immediate defense response by 
inducing the production of pro-inflammatory 
cytokines, which rapidly destroy or limit the 
pathogens (1). In their bridging role, TLR 
downstream signals link innate and adaptive 
immunity, particularly by mediating dendritic cells 
(DCs) maturation and activation of pathogen specific 
T lymphocytes. These pathways lead to the activation 
of professional antigen presenting cells (APCs), 
which is followed by enhanced expression of surface 
molecules, MHC and co-stimulatory molecules 
[CD40, CD80, CD86 and CD70] (2). TLRs are 
expressed in a variety of cell types, mostly within the 
immune system where they have been linked to 
different cellular activation states, immune defense, 
maintenance of homeostasis, and various diseases (3). 
TLRs and related immunological pathways are being 
extensively studied for research, diagnostic and 
therapeutic purposes. Most mammalian species have 
between ten and fifteen types of TLRs. Ten functional 
TLRs (TLR1-10) have been identified in human. 
Structure of TLRs 
TLR family is a member of interleukin-1 
receptor (IL-1R)/TLR superfamily, as a family of type 
I transmembrane proteins that contain a TIR 
intracellular domain. All TLRs have a common basic 
structure (4, 5): 
1. N-terminal extracellular or ectodomain (ECD) 
containing leucine rich repeat (LRR) modules and a 
60 amino acid (AA) domain rich in cysteine 
2. Transmembrane domain 
3. C-terminal intracellular globular domain 
containing a conserved region which has high 
homology with mammalian IL-1R family members. 
This region is called the Toll/IL-1 receptor (TIR) 
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domain 
Both TLR dimerization and the TIR domains 
are required for signal transduction. Both extracellular 
and intracellular membrane-bound (endosomal) TLR4 
requires its co-receptor MD2 to recognize LPS. 
Dimerization of the TLR4-MD2 complex with 
another TLR4-MD2 complex occurs following 
binding of LPS. The structure showed that LPS bound 
to two symmetrically arranged copies of TLR4 and 
MD2. TLR4 forms hydrophobic and hydrophilic 
interactions with LPS, which is required for TLR4 
dimerization to occur (5, 6). 
Ligands of TLR4 
A large body of interest has centered on 
ligands of TLR4. There are 2 types of ligands for 
TLR4: endogenous and exogenous. Endogenous 
ligands are not produced under physiologic 
conditions. Protozoa, LPS of bacteria, fungi, and 
viruses are considered as exogenous ligands for TLR4 
(7, 8). 
It is well recognized that ligand-induced TLR 
activation is a double-edge sword. On the one hand, 
exogenous ligands initiate a quick immune response 
through the TLR system and also excessive TLR 
activation can lead to massive inflammation, tissue 
damage and cell death. The injured and dying cells 
release endogenous ligands that in turn can activate 
TLR pathways, causing more and more tissue damage 
and ligand release, thereby causing more destructions 
(7-9). 
Expression 
In general, TLRs are vastly expressed in 
immune cells, including macrophages, dendritic cells, 
neutrophils, mucosal epithelial cells and dermal 
endothelial cells. However, TLRs have also now been 
identified in numerous other cell types and tissues. 
The most important sites of TLR4 expression are 
summarized in table 2. Monocytes and macrophages 
are important for this context. 
TLR4 Signal transduction 
Circulating LBP recognizes LPS in the plasma 
and brings it to CD14. This aids the loading of LPS 
onto the LPS receptor complex, which is composed of 
dimerizedTLR4 receptors and two molecules of the 
extracellular adapter MD-2. Subsequent signals 
activated by TLR4 can be subdivided into those 
dependent on MyD88 and MAL, which occur early 
and those independent of MyD88, which occur later 
and use the adapters TRIF and TRAM. Signaling 
caused by LPS leads to the early activation of NF-κB, 
IRF3 and MAP kinase pathways which are mediated 
by the adapters MyD88 and Mal. After the subsequent 
activation and phosphorylation of IRAK, TRAF6 
becomes activated which gives rise to the expression 
of numerous pro-inflammatory genes. As a later 
response to LPS, TLR4 gives rise to the activation of 
TRAF6 and TBK1, an event mediated by the adapters 
TRIF and TRAM (10). 
CD14 
CD14 is widely used as a 
monocyte/macrophage marker in flowcytometry as 
well as immunohistochemistry. CD14 is a 55 kDa 
glycoprotein with multiple leucine-rich repeats. It is 
encoded on chromosome 5q23–31, together with IL-
3, GM-CSF, epidermal growth factor (EGF) receptor, 
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β adrenergic receptor and platelet derived growth 
factor (PDGF). CD14 is attached to the cell 
membrane via a glycosylphosphatidylinositol (GPI) 
anchor. Monocytes or macrophages shed CD14 to 
facilitate LPS signaling for all other cells in 
conjunction with lipopolysaccharide binding protein 
(LBP) and, TLR4 (11). 
Products of mononuclear 
cells 
Mononuclear are capable of producing many 
substances that can influence the host. Presence of a 
stimulus is required for activation of these cells. 
Following activation, signaling cascades produce 
various substances. Enzymes, reactive oxygen 
species, reactive nitrogen species, bioactive lipids and 
cytokines are produced by macrophages. 
Macrophages are particularly important sources of 
TNF-α, IL-l, lL-6, IL-8, and IL-12 (12, 13). IL-l is a 
major mediator of local and systemic inflammation. It 
is secreted in response to diverse stimuli including 
bacterial infection, viral infection, tissue trauma, and 
tumors. It can stimulate proliferation of T and B 
lymphocytes; cause hyperthermia by an action 
through hypothalamic cells; alter synovial cell 
synthesis of prostaglandins, collagenase, and 
plasminogen activator; enhance fibroblast 
proliferation; enhance catabolic activities in muscle; 
cause specific granule release from neutrophils; and 
cause hepatocyte synthesis of acute-phase reactants 
(14). TNF-α is the prototype for a large family of 
cytokines, which have important roles in immunity. 
TNF-α is secreted by macrophages after exposure to 
endotoxin. It binds either a 55-kD or 75-kD receptor. 
The members of TNF-α family have multiple 
activities that include beneficial functions for 
organogenesis, inflammation, and host defense. 
However, overproduction of TNF-α can lead to 
cachexia, sepsis, and autoimmune disease (15). 
DISCUSSION 
Concepts of TLR4 in Disease 
TLR4 and stenosis of coronary 
vessels 
As plaque encroaches into the lumen, the 
coronary artery diameter decreases. Luminal 
narrowing of more than 60 percent may result in 
transient ischemia and angina. More importantly, 
there is a poor correlation between the severity of 
stenosis and its propensity to cause myocardial 
infarction or sudden cardiac death (18). TLR4 
involvement in coronary stenosis is not 
mechanistically understood. It is proposed that 
gradual infiltration of TLR4+ monocytes in 
developing plaques and production of cytokines in 
concert with other important players can deteriorate 
atherosclerosis. Up regulation in TLR4 and pro-
inflammatory cytokines and increased arterial 
remodeling may impair vasodilatation, reduce 
coronary flow and thus contribute to facilitate 
Table 2: TLR4 expression in cells and tissues 
(7-9). 
Cell type Tissue 
B cells Active pouchitis 
Basophiles Aortic valve cells 
CD4+ T cells Bone marrow 
CD8+ T cells Brain (microglia cells) 
Endothelial cells Colonic epithelium 
Immature DCs Female reproductive system 
Macrophages Ileum 
Mast cells Lymph node 
Monocytes Ovary 
Myeloid DCs Pulmonary epithelium 
Neutrophils Rectum 
Platelets Renal epithelium 
Splenocytes Small intestinal epithelium 
T cells Ureter epithelium 
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ischemic damages (19). 
TLR4 and lung injuries 
The stimulation of inflammatory cytokines can 
up-regulate the secretion of TLR4, MyD88 and NF-
κB. TLR4-MyD88 signaling plays an important role 
in the development of ventilator-induced lung injury 
in rats (20). Current findings suggest that injurious 
mechanical ventilation (MV) may elicit an immune 
response that is similar to that observed during severe 
infections. Further studies are needed to fully address 
these questions. It is observed that mechanical 
ventilation with tidal volumes of 40 mL/kg increased 
lung permeability and induced inflammation. The 
mechanism of action of mechanical ventilation may 
involve increasing in TLR2, TLR4, and TLR9 and 
MyD88 expressions (21). Studies supports an 
interaction betweenTLR2, TLR4, and TLR9 and 
MyD88 signaling pathway for the over expression 
and release of pro-inflammatory cytokines during 
VILI. Further investigation to identify the exact 
functions of TLR families will provide crucial insight 
into designing new interventions to limit lung injury 
induced by mechanical ventilation (21). 
TLR4 and drugs 
Glucocorticoids can up regulate the 
cytoplasmic inhibitor of NF-κB, I-κB and thus inhibit 
translocation.  In addition, glucocorticoids have 
inhibitory effects on genes for inducible nitric oxide 
synthase (NOS), cyclooxygenase-2 (COX-2) and 
inflammatory cytokines (22). These results highlight 
the distinguished role of glucocorticoids as anti-
inflammatory and immunosuppressive agents. 
Significant data support the expression of TLR4 on 
the surface of monocytes not only in the blood but 
also in arterial intima during atherogenesis. Recent 
data suggest that angiotensin-converting enzyme 2 
(ACE2) possess anti-inflammatory effects by 
suppression of TNF-α and IL-6 release (23). It might 
be possible that part of ACE2 mechanism of action is 
mediated through hTLR4 inhibition in atherosclerotic 
lesions. Our previous study showed that 
hydrocortisone was able to reduce monocyte 
expression of TLR4 in patients with stable angina 
(24). Multiple experimental and clinical studies 
support additional activity of statins beyond their 
serum cholesterol-lowering effects. However, little is 
known about the mechanisms underlying these anti-
inflammatory effects of statins. Statins reduce TLR4 
surface expression on CD14+ monocytes in vivo and 
ex vivo in a dose dependent fashion and reduced 
expression of pro-inflammatory cytokines. Previous 
observations showing that statins are able to suppress 
oxidized low-density lipoprotein induced NF-κB 
expression and that oxidized low-density lipoprotein 
up-regulates TLR expression in human macrophages. 
Among the potential pathways, inhibition of protein 
prenylation or of lymphocyte function-associated 
antigen-1 might be key components mediating the 
rapid effect of statins (25, 26). Quite recent data 
showed that simvastatin or the combination of 
simvastatin with ezetimibe reduced TLR4 expression 
and IL-6 and IL-1β production in monocytes of 
hypercholesterolemic patients (27). Additionally, 
Eritoran is a second-generation structural analog of 
the lipid A portion of LPS. In in vivo and in vitro 
models, eritoran has been shown to be a potent 
antagonist of the biochemical and physiological 
effects of LPS by blocking translocation of NF-κB, 
which results in decreased expression of 
inflammatory cytokines. It is shown in a mouse model 
that the inhibition of TLR4 by its antagonist eritoran 
attenuates the inflammatory response to MI/R, as 
evidenced by a significant reduction in infarct size 
decreased NF-κB nuclear translocation, and decreased 
expression of inflammatory mediators, such as TNF-
α, IL-1β and IL-6 (28). Eritoran has been shown to be 
safe in humans and it is currently undergoing clinical 
development as a possible therapeutic agent for the 
treatment of sepsis and for myocardial protection 
during coronary artery bypass grafting. However, the 
primary results are not promising. Beneficial effects 
of glucocorticoids in reduction of TLR4 expression 
and incidence of ventilator-induced lung injuries 
should be adequately assessed. Furthermore, an 
effective and standard therapy to prevent such injuries 
should be ascertained. 
Conclusion 
TLRs are link between the development of 
ventilator- induced lung injuries and the immune 
system. Current evidence supports the theory that 
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TLR activation contributes to the development and 
progression of lung injures during ventilation. The 
therapeutic potential of TLRs should be further 
studied in basic and clinical settings. 
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